Bio-Techne Corp (TECH) To Go Ex-Dividend on August 17th

Bio-Techne Corp (NASDAQ:TECH) announced a quarterly dividend on Wednesday, August 12th. Investors of record on Monday, August 17th will be paid a dividend of 0.08 per share by the biotechnology company on Friday, August 28th. This represents a c) annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, August 17th.

Bio-Techne has a dividend payout ratio of 15.4% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Bio-Techne to earn $2.01 per share next year, which means the company should continue to be able to cover its $0.32 annual dividend with an expected future payout ratio of 15.9%.

Bio-Techne Stock Down 0.1%

NASDAQ TECH opened at $72.17 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.18 and a current ratio of 4.49. The firm has a 50-day simple moving average of $66.99 and a 200 day simple moving average of $59.22. Bio-Techne has a twelve month low of $43.19 and a twelve month high of $72.39. The stock has a market cap of $11.30 billion, a PE ratio of 62.76, a PEG ratio of 8.60 and a beta of 1.28.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.52. Bio-Techne had a return on equity of 13.37% and a net margin of 14.97%.The firm had revenue of $321.19 million for the quarter, compared to analyst estimates of $314.63 million. During the same period in the previous year, the company posted $0.53 earnings per share. The company’s quarterly revenue was up 1.3% compared to the same quarter last year. On average, research analysts forecast that Bio-Techne will post 1.76 EPS for the current year.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.